Skip to main content

← All glossary terms

Glossary · Unite, Steward

Publication review

Publication review is a clause in a research agreement that gives the sponsor a limited period to read a manuscript, thesis, or presentation before it's submitted, so the sponsor can identify its confidential information for removal and decide whether to file a patent first. It isn't a right to approve, change, or block the publication.

How it works in a university-industry collaboration

The university will publish. What the sponsor negotiates is the window and the delay. The UIDP Contract Accords set out the agreed middle: the sponsor gets a short review period (30 days is common), may ask for its confidential information to be removed, and may ask for a further short delay to file a patent, after which the researchers publish. A dissertation carve-out protects a student's defense from being held for a filing decision. Nothing in the standard form lets the sponsor edit the science or decide whether results appear.

The evidence on what institutions accept is consistent. In a survey of 107 academic medical centers, 96% would accept a limited-time review, 89% considered sponsor authority to revise a manuscript impermissible, and 93% said the same of authority to decide whether results are published. Asked the longest review they'd allow, 44% said 60 days and 31% said 90 (Mello, Clarridge, and Studdert, NEJM, 2005). On the trial side, a review of 647 randomized-trial protocols found that 86.2% of the publication agreements gave the sponsor review or disapproval rights, which is why journals and institutions now look at these clauses closely (Kasenda et al., PLoS Medicine, 2016). A publication restriction can also cost a project its fundamental-research exclusion from export control, which is one more reason universities hold the line.

Translation Box: publication review

On the academic side: a courtesy window, and the clock a student's defense may be waiting on. "Review" means the sponsor reads it, not that the sponsor approves it.

On the industry side: often drafted as "approval," because that's what the company's own publications policy says. Change the word, keep the window, and add the patent delay you actually need.

What Helikon does with it

A review window is a dated obligation, and on Helikon it's tracked as a project milestone with its due date and reminder emails, so the manuscript goes to the sponsor on time and the clock is visible to both sides.

Sources

  • Mello, M. M., Clarridge, B. R., and Studdert, D. M., 2005, Academic medical centers' standards for clinical-trial agreements with industry, New England Journal of Medicine 352(21), 2202-2210. doi.org/10.1056/NEJMsa044115
  • Kasenda, B., et al., 2016, Agreements between industry and academia on publication rights: a retrospective study of protocols and publications of randomized clinical trials, PLoS Medicine 13(6), e1002046. doi.org/10.1371/journal.pmed.1002046
  • UIDP, 2020, Contract Accords for University-Industry Sponsored Agreements (Accord 3, Publications). uidp.org/publication/contract-accords-2020/

Related